Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined application of ginsenoside and berberine or berberine salt to preparation of drugs for treating atherosclerosis or hyperlipidemia

A technology for atherosclerosis and ginsenosides, applied in the field of pharmacy, to achieve good application prospects, reduce expression, excellent atherosclerosis and hyperlipidemia effects

Inactive Publication Date: 2017-09-15
GUANGDONG PHARMA UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Both ginsenoside and berberine have been reported to have blood lipid-lowering effects, but there is no literature report on the combined use of ginsenoside and berberine for lowering blood lipids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined application of ginsenoside and berberine or berberine salt to preparation of drugs for treating atherosclerosis or hyperlipidemia
  • Combined application of ginsenoside and berberine or berberine salt to preparation of drugs for treating atherosclerosis or hyperlipidemia
  • Combined application of ginsenoside and berberine or berberine salt to preparation of drugs for treating atherosclerosis or hyperlipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Effect of ginsenoside Rb1 combined with berberine hydrochloride on the formation of RAW264.7 macrophage foam cells

[0037] 1.1 Cell culture and modeling

[0038] The cells used in the experiment were RAW264.7 macrophage cell line. Preparation of complete medium: high glucose (DMEM) medium containing 10% fetal bovine serum (FBS), 1% penicillin and streptomycin mixed solution. placed in 5% CO 2, cultured in a cell incubator at 37°C. When the cell fusion reached 75%, the cells were subcultured: 0.25% trypsin was digested for 1 mim, the adherent cells were blown gently, the cell suspension was transferred to a centrifuge tube, and centrifuged at 800r / min for 5min. Discard the supernatant, add complete cell culture medium to resuspend the cells, transfer them to a new culture dish with a pipette, and place in 5% CO 2 , cultured in a 37°C incubator.

[0039] Establish foam cell model: RAW264.7 macrophage cell line at 1×10 5 Inoculated on a 24-control plate an...

Embodiment 2

[0064] Example 2 Ginsenoside Rb 1 Effects of Combined Administration with Berberine Hydrochloride on Cholesterol Ester Content in RAW264.7 Macrophages

[0065] The culture medium was divided into 5 categories according to the experimental treatment requirements, corresponding to the corresponding cell culture groups: blank group (no FBS medium); model group, ginsenoside Rb 1 Combined with berberine hydrochloride (berberine hydrochloride: ginsenoside Rb 1 =9:1), ginsenoside Rb1 group, berberine hydrochloride. After incubation with complete medium containing 10% FBS for 5 days, the medium was removed, washed twice with PBS, fixed with 4% paraformaldehyde for 10 min, washed three times with PBS, and then the oil red O stock solution was mixed with pure water at a ratio of 3:2. Let stand for 10min. Filter on filter paper. The filtrate was added to the dish and stained in the dark for 5 minutes. Remove the Oil Red O working solution, add 60% isopropanol solution, wash once, wa...

Embodiment 3

[0067] Example 3 Ginsenoside Rb 1 Effects of combination with berberine hydrochloride on the viability of RAW264.7 macrophages

[0068] High glucose (DMEM) medium containing 10% fetal bovine serum (FBS), 1% penicillin and streptomycin mixed solution. placed in 5% CO 2 , cultured in a cell incubator at 37°C. When the cell fusion reached 75%, the cells were subcultured: 0.25% trypsin was digested for 1 mim, the adherent cells were blown gently, the cell suspension was transferred to a centrifuge tube, and centrifuged at 800r / min for 5min. Discard the supernatant, add complete cell culture medium to resuspend the cells, transfer them to a new culture dish with a pipette, and place in 5% CO 2 , cultured in a 37°C incubator.

[0069] RAW264.7 macrophage cell line with 1×10 5 Inoculated on a 24-control plate and incubated in a CO2 incubator at 37°C for 24 hours. After the cells grew well, they were incubated with complete medium containing 40% FBS for 5 days, and the medium was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of pharmacy and particularly discloses combined application of ginsenoside and berberine or a berberine salt to preparation of drugs for treating atherosclerosis or hyperlipidemia. The ginsenoside is selected from ginsenoside Rb1, and the berberine salt is selected from berberine hydrochloride. The invention further provides a pharmaceutical composition. The pharmaceutical composition comprises the ginsenoside and the berberine or the berberine salt, and a mass ratio of the ginsenoside to the berberine or the berberine salt is 1-10:1-10. The pharmaceutical composition is remarkably effective in prevention and treatment of the atherosclerosis and hyperlipidemia and is exact in efficacy, safe and free of obvious toxic and side effects, thereby being promising in application prospect.

Description

technical field [0001] The invention relates to the technical field of pharmacy, in particular to the application of ginsenoside combined with berberine or berberine salt in the preparation of medicine for treating atherosclerosis or hyperlipidemia. Background technique [0002] Hyperlipidemia refers to excessive blood lipid levels, which can directly cause some diseases that seriously endanger human health, such as atherosclerosis, coronary heart disease, pancreatitis, etc. Atherosclerosis (AS) is the main cause of coronary heart disease, cerebral infarction and peripheral vascular disease. Lipid metabolism disorder is the basis of atherosclerosis, which is characterized by the involvement of arterial lesions starting from the intima, usually with accumulation of lipids and complex carbohydrates, hemorrhage and thrombosis, followed by fibrous tissue hyperplasia and calcium deposition, followed by There is gradual degeneration and calcification of the arterial media, result...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/4375A61P3/06A61P9/10
CPCA61K31/4375A61K31/704A61K2300/00
Inventor 罗朵生郭姣孙玲荣向路
Owner GUANGDONG PHARMA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com